“Sihir” den “Tedavi” ye Mantarlar

Gül Baktır

“Sihir” den “Tedavi” ye Mantarlar

Abstract

Psikedelikler algı, biliş ve ruh halinde değişikliklere yol açabilen, halüsinojenik etkileri bulunan serotonin 5-HT2A reseptör agonistleridir. Bu derleme makalede, LSD, dimetiltriptamin, meskalin gibi “klasik psikedelikler” sınıfına dahil olan psilosibin ve psilosin’ in kimyasal ve farmakolojik özellikleri ile tedavide kullanım potansiyelleri incelenmektedir. Psikedeliklerin tedavide kullanımlarına ilişkin çalışmalar ilaç endüstrisi tarafından uzun bir süre ihmal edilmişse de, yakın tarihli klinik araştırmalar özellikle psilosibin destekli psikoterapinin depresyon, kansere bağlı anksiyete, tedaviye dirençli depresyon gibi endikasyonlarda etkili olabileceğini göstermiştir. Psilosibin destekli tedavilerin umut vaat etmesi üzerine, FDA psilosibin’e tedaviye dirençli depresyon için "Çığır Açan Tedavi" statüsü onayı vererek, mevcut tedavi seçeneklerine göre avantaj gösterebileceğini kabul etmiştir. Yeni ilaç keşfine ilişkin araştırma-geliştirme programlarının temel koşulları olan fon sağlama ve sağlık otoritelerince belirlenen yasal düzenlemelere uyma zorunluluğu nedeniyle bu araştırmalardan sağlanabilecek terapötik faydanın hastalara ulaşabilmesi, hükümetlerin, ilaç şirketlerinin ve kâr amacı gütmeyen kuruluşların birlikte çalışmalarını gerekli kılmaktadır. Psilosibin ile çok çeşitli psikiyatrik endikasyonlarda çok sayıda klinik araştırma halen devam etmekte olup FDA nezdinde “yeni ilaç ruhsat başvurusu” yapılması durumunda mevcut yasal sınıflandırmasında da değişikliğe gidilmesi söz konusu olacaktır.

Keywords

References

[1] Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651.
[2] Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia-Romeu, A., & Garcia-Barrera, M. A. (2023). Psilocybin’s effects on cognition and creativity: A scoping review. Journal of Psychopharmacology, 37(7), 635-648.
[3] Nichols, D. E. (2020). Psilocybin: from ancient magic to modern medicine. The Journal of antibiotics, 73(10), 679- 686.
[4] Matsushima, Y., Eguchi, F., Kikukawa, T., & Matsuda, T. (2009). Historical overview of psychoactive mushrooms. Inflammation and Regeneration, 29 (1), 47–58.
[5] Nichols, D. E. (2016). Psychedelics. Pharmacological reviews, 68(2), 264-355.
[6] Guzmán, G., Allen, J. W., & Gartz, J. (1998). A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. Ann Mus Civ Rovereto, 14, 189-280.
[7] Hofmann, A., Heim, R., Brack, A., & Kobel, H. A. N. S. (1958). Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experientia, 14, 107-109.
[8] Blei, F., Dörner, S., Fricke, J., Baldeweg, F., Trottmann, F., Komor, A., & Hoffmeister, D. (2020). Simultaneous production of psilocybin and a cocktail of β‐carboline monoamine oxidase inhibitors in “magic” mushrooms. Chemistry– A European Journal, 26(3), 729-734.

[9] Tay, T. L., Savage, J. C., Hui, C. W., Bisht, K., & Tremblay, M. È. (2017). Microglia across the lifespan: from origin to function in brain development, plasticity and cognition. The Journal of physiology, 595(6), 1929-1945.
[10] VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben-Azu, B., & Tremblay, M. È. (2023). The missing piece? A case for microglia’s prominent role in the therapeutic action of anesthetics, ketamine, and psychedelics. Neurochemical research, 48(4), 1129-1166.
[11] De Veen, B. T., Schellekens, A. F., Verheij, M. M., & Homberg, J. R. (2017). Psilocybin for treating substance use disorders?. Expert review of neurotherapeutics, 17(2), 203-212.
[12] Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., & Müller, C. P. (2017). Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs. Frontiers in psychiatry, 8, 152.
[13] Chávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas-Quintero, J. (2019). Depression as a neuroendocrine disorder: emerging neuropsychopharmacological approaches beyond monoamines. Advances in Pharmacological and Pharmaceutical Sciences, 2019(1), 7943481.
[14] Mahapatra, A., & Gupta, R. (2017). Role of psilocybin in the treatment of depression. Therapeutic advances in psychopharmacology, 7(1), 54-56.
[15] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M.,Reed, L. J., Colasanti, A., & Nutt, D. J. (2012). Neural correlatesof the psychedelic state as determined by fMRIstudies with psilocybin. Proceedings of the National Academyof Sciences, 109(6), 2138-2143.
[16] Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., & McMurray, M. S. (2024). Pharmacological and behavioural effects of tryptamines present in psilocybin‐ containing mushrooms. British Journal of Pharmacology, 181(19), 3627-3641.
[17] Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14, 734-740.
[18] Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166.
[19] Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology, 29(3), 289-299.
[20] Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of clinical Psychiatry, 67(11), 1735-1740.
[21] Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology, 28(11), 983-992.
[22] Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.
[23] Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry, 78(5), 481-489.
[24] Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197.
[25] Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology, 30(12), 1165-1180.
[26] Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., & Malievskaia, E. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48(10), 1492- 1499.
[27] Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research, 284, 112749.
[28] Vargas, A. S., Luís, Â., Barroso, M., Gallardo, E., & Pereira, L. (2020). Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Biomedicines, 8(9), 331.
[29] Yu, C. L., Yang, F. C., Yang, S. N., Tseng, P. T., Stubbs, B., Yeh, T. C., & Liang, C. S. (2021). Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investigation, 18(10), 958.
[30] Jann, M. W. (2021). Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potential. Psychiatric Times, 38(3).
[31] Psilocybin-COMPASS Pathways website.https://adisinsight.springer.com/drugs/800050861. Accessed May 21, 2025.
[32] Watson, J. R., Halpin, L., Barroso, V., Dahdouh, G., Bursalyan, J., Mohta, S., & Serrano, J. L. (2025). A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics. The Permanente Journal, 29(1), 89.
[33] ClinicalTrials.gov website. https://clinicaltrials.gov/search?term=psilocybin&viewType= Table. Accessed May 21, 2025.
[34] FDA News Release. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. https://www.fda.gov/news-events/press-announcements/ fda-approves-new-nasal-spray-medication-treatment- resistant-depression-available-only-certified. Accessed May 21, 2025.
[35] Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: a review. CNS neuroscience & therapeutics, 14(4), 295-314.
[36] Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.
[37] Chen, C. Y., Storr, C. L., & Anthony, J. C. (2009). Early-onset drug use and risk for drug dependence problems. Addictive behaviors, 34(3), 319-322.
[38] Kaminski, D., & Reinert, J. P. (2024). The tolerability and safety of psilocybin in psychiatric and substance-dependence Journal of PhytoPharmacy Derleme / Review Volume 1 Issue 1 http://jpp.yeniyuzyil.edu.tr Journal of PhytoPharmacy 8 conditions: a systematic review. Annals of Pharmacotherapy,58(8), 811-826.
[39] 1971 Convention on Psychotropic Substances https://web.archive.org/web/20180209061927/https:// www.unodc.org/pdf/convention_1971_en.pdf. Accessed May 21, 2025.
[40] Johns Hopkins Medicine; News & Publications - Newsroom; Reclassification Recommendations for Drug in ‘Magic Mushrooms’; https://www.hopkinsmedicine.org/news/ newsroom/news-releases/2018/09/reclassification-recommendations-for-drug-in-magic-mushrooms. Accessed May 21, 2025.
[41] 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun (R. Gazete: Tarih: 24/6/1933, Sayı: 2435)
[42] 5237 Sayılı Türk Ceza Kanunu (R. Gazete: Tarih: 12/10/2004, Sayı: 25611).
[43] 7445 Sayılı İcra ve İflas Kanunu ile Bazı Kanunlarda Değişiklik Yapılmasına Dair Kanun (R. Gazete: Tarih: 05/04/2023, Sayı: 32154).

Details

Primary Language

Turkish

Subjects

Basic Pharmacology

Journal Section

Review

Authors

Gül Baktır ^*
0000-0002-8471-4777
Türkiye

Publication Date

May 29, 2025

Submission Date

May 5, 2025

Acceptance Date

May 23, 2025

Published in Issue

Year 2025 Volume: 1 Number: 1

IZ

https://izlik.org/JA59PT96UC

Cite

RIS / Bibtex

APA

Baktır, G. (2025). “Sihir” den “Tedavi” ye Mantarlar. IYYU Journal of PhytoPharmacy, 1(1), 1-8. https://izlik.org/JA59PT96UC

AMA

1.Baktır G. “Sihir” den “Tedavi” ye Mantarlar. JPP. 2025;1(1):1-8. https://izlik.org/JA59PT96UC

Chicago

Baktır, Gül. 2025. ““Sihir” Den ‘Tedavi’ Ye Mantarlar”. IYYU Journal of PhytoPharmacy 1 (1): 1-8. https://izlik.org/JA59PT96UC.

EndNote

Baktır G (May 1, 2025) “Sihir” den “Tedavi” ye Mantarlar. IYYU Journal of PhytoPharmacy 1 1 1–8.

IEEE

[1]G. Baktır, ““Sihir” den ‘Tedavi’ ye Mantarlar”, JPP, vol. 1, no. 1, pp. 1–8, May 2025, [Online]. Available: https://izlik.org/JA59PT96UC

ISNAD

Baktır, Gül. ““Sihir” Den ‘Tedavi’ Ye Mantarlar”. IYYU Journal of PhytoPharmacy 1/1 (May 1, 2025): 1-8. https://izlik.org/JA59PT96UC.

JAMA

1.Baktır G. “Sihir” den “Tedavi” ye Mantarlar. JPP. 2025;1:1–8.

MLA

Baktır, Gül. ““Sihir” Den ‘Tedavi’ Ye Mantarlar”. IYYU Journal of PhytoPharmacy, vol. 1, no. 1, May 2025, pp. 1-8, https://izlik.org/JA59PT96UC.

Vancouver

1.Gül Baktır. “Sihir” den “Tedavi” ye Mantarlar. JPP [Internet]. 2025 May 1;1(1):1-8. Available from: https://izlik.org/JA59PT96UC